Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Myelodysplastic Syndromes 26Hematologic Neoplasms 20Lymphoma, Non-Hodgkin 19Multiple Myeloma 18Lymphoma 18Recurrence 15Lymphoma, B-Cell 14Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Breast Neoplasms 11Pancreatic Neoplasms 10Ovarian Neoplasms 10Lymphoma, Follicular 10Neoplasm Metastasis 9Melanoma 9Leukemia, Myelomonocytic, Chronic 9Myeloproliferative Disorders 8Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Leukemia, Biphenotypic, Acute 7Leukemia 7Hodgkin Disease 7Glioblastoma 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Osteosarcoma 6

Interventions

fludarabine 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2 Positive Advanced Solid Tumors × fludarabine × Clear all
NCT05681650 2023-12-12

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
30 enrolled
Other solid neoplasm

HER2 Positive Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡